Constructing Chimeric Antigen for Precise Screening of HTLV-I Infection

Area of Science:

• Virology
• Immunology
• Biotechnology

Background:

• Human T-cell lymphotropic virus type I (HTLV-I) diagnostics rely on individual peptide preparations (MTA-1, GD21), which are costly and time-consuming.
• Developing cost-effective and efficient diagnostic reagents for HTLV-I is crucial for disease screening and management.

Purpose of the Study:

• To design and evaluate a novel single chimeric antigen (SCA) for HTLV-I detection.
• To reduce the cost and complexity of HTLV-I diagnostic reagent preparation through a unified antigen approach.

Main Methods:

• Selected immunodominant B cell linear epitopes from HTLV-I structural proteins.
• Designed and computationally analyzed multiple SCAs for tertiary structure, epitope exposure, solubility, and stability.
• Synthesized DNA encoding the optimal SCA, sub-cloned it into a pET32a expression vector, and expressed it in Escherichia coli BL21 (DE3) cells.
• Purified the recombinant thioredoxin-fused SCA under native conditions using affinity chromatography and confirmed expression via SDS-PAGE.
• Validated the SCA's reactivity with anti-HTLV-I antibodies using Enzyme-Linked Immunosorbent Assay (ELISA).

Main Results:

• Successfully designed and expressed a soluble thioredoxin-fused SCA in E. coli.
• Demonstrated that the SCA reacts with anti-HTLV-I antibodies in a concentration-dependent manner via ELISA.
• Computational analysis predicted favorable structural properties for the designed SCA.

Conclusions:

• The developed single chimeric antigen (SCA) offers a simplified and potentially more cost-effective alternative to individual peptide preparations for HTLV-I diagnostics.
• The SCA shows significant potential as a candidate reagent for antigen-antibody-based screening tests to identify HTLV-I carriers.